[
    [
        {
            "time": "2021-08-16",
            "original_text": "安图生物(603658)：业绩基本符合预期 疫情影响仍然存在",
            "features": {
                "keywords": [
                    "安图生物",
                    "业绩",
                    "疫情"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "安图生物(603658)：业绩基本符合预期 疫情影响仍然存在",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-17",
            "original_text": "安图生物2021年中报点评：业绩基本符合我们预期，看好公司化学发光成长与平台化业务拓展！【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "安图生物",
                    "中报",
                    "化学发光",
                    "平台化业务"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "安图生物2021年中报点评：业绩基本符合我们预期，看好公司化学发光成长与平台化业务拓展！【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-18",
            "original_text": "安图生物(603658)：研发持续加大 核心业务高增长",
            "features": {
                "keywords": [
                    "安图生物",
                    "研发",
                    "核心业务",
                    "高增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物(603658)：研发持续加大 核心业务高增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "裘国根、邓晓峰、冯柳、林利军等私募大佬持仓动向",
            "features": {
                "keywords": [
                    "裘国根",
                    "邓晓峰",
                    "冯柳",
                    "林利军",
                    "私募",
                    "持仓"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "裘国根、邓晓峰、冯柳、林利军等私募大佬持仓动向",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-08-20",
            "original_text": "快讯 | 安图生物2021半年报：上半年营业收入为16.78亿元，同比增加39.13%",
            "features": {
                "keywords": [
                    "安图生物",
                    "半年报",
                    "营业收入",
                    "同比增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "快讯 | 安图生物2021半年报：上半年营业收入为16.78亿元，同比增加39.13%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-21",
            "original_text": "上半年安图生物净利增长超五成 股价下行难挡北向资金连续三季度加仓",
            "features": {
                "keywords": [
                    "安图生物",
                    "净利增长",
                    "股价下行",
                    "北向资金",
                    "加仓"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "上半年安图生物净利增长超五成 股价下行难挡北向资金连续三季度加仓",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-22",
            "original_text": "安图生物(603658)：疫情反复致二季度恢复放缓 化学发光有望带动公司全年业绩稳健增长",
            "features": {
                "keywords": [
                    "安图生物",
                    "疫情反复",
                    "化学发光",
                    "业绩增长"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物(603658)：疫情反复致二季度恢复放缓 化学发光有望带动公司全年业绩稳健增长",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-23",
            "original_text": "安图生物(603658)：上半年化学发光业务实现恢复性增长 进军分子诊断",
            "features": {
                "keywords": [
                    "安图生物",
                    "化学发光",
                    "恢复性增长",
                    "分子诊断"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物(603658)：上半年化学发光业务实现恢复性增长 进军分子诊断",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]